對未經(jīng)治療的晚期非小細(xì)胞肺癌患者分別給予雙環(huán)鉑合用紫杉醇與卡鉑合用紫杉醇進(jìn)行比較的Ⅱ期臨床研究.pdf

1、中山大學(xué)碩士學(xué)位論文對未經(jīng)治療的晚期非小細(xì)胞肺癌患者分別給予雙環(huán)鉑合用紫杉醇與卡鉑合用紫杉醇進(jìn)行比較的Ⅱ期臨床研究姓名：彭晉申請學(xué)位級別：碩士專業(yè)：腫瘤學(xué)指導(dǎo)教師：吳海鷹20080520中山大學(xué)碩士學(xué)位論文PhaseIIClinicalTrialofDicycloplatinPlusPaclitaxelComparedwithCarboplatinPlusPaclitaxelinChemotherapy—naivePatientswit

2、hAdvancedNonsmall—cellLungCancerABSTI認(rèn)CTPurpose：Toinvestigatetheefficacyandtoxicityofdicyclorplatinpluspaclitaxelcomparedwithcarboplatinpluspaclitaxelinchemotherapynaivepatientswithadvancednon—smallcelllungcancer(NSCLC)M

3、ethods：Itisamulticenterrandomized，comparable，openedphaseIIclinicaltrialPatientsmetthecriteriawererandomlyassignedtoexperimentalarmofdicycloplatinpluspaclitaxelorcontrolarmofcarboplatinpluspaclitaxelTheexperimentalarlflwa

4、sgivendicycloplatin450mg／m2pluspaclitaxel175mg／m2q3w，andthecontrolarmwasgivencarboplatinAUC=5pluspaclitaxel175mg／m2q3wResponserateandadversereactionswereevaluatedaccordingtECISTcriteriaandsurvivalfollowupwasperformedResu

5、lts：Atotalof108patientsmetthecriteriawereenteredthestudywith40patientsbeingstageIIIband68stageIVThemedianfollowuptimewas107monthsThesepatientswererandomizedintotwoarms，fiftyfivepatientsintheexperimentalarmand53inthecontr

6、olarmThetwotreatmentarmswerewellbalancedwithregardtogenderage，performancestatus，stageandhistologyTheoverallresponseratesofexperimentalaITflandcontrolantiwere291％and300％(p=0901)respectivelythemediansurvivalwas10monthsand9